MX2020005472A - Sistemas de administración de fármacos a base de maitansinoide. - Google Patents

Sistemas de administración de fármacos a base de maitansinoide.

Info

Publication number
MX2020005472A
MX2020005472A MX2020005472A MX2020005472A MX2020005472A MX 2020005472 A MX2020005472 A MX 2020005472A MX 2020005472 A MX2020005472 A MX 2020005472A MX 2020005472 A MX2020005472 A MX 2020005472A MX 2020005472 A MX2020005472 A MX 2020005472A
Authority
MX
Mexico
Prior art keywords
maytansinoid
drug delivery
delivery systems
based drug
albumin
Prior art date
Application number
MX2020005472A
Other languages
English (en)
Inventor
Felix Kratz
Ajaj Khalid Abu
Stephan David Koester
Friederike I Nollmann
Fernandez Javier Garcia
Anna Warnecke
Lara Pes
Heidi-Kristin Walter
Johannes Pall Magnusson
Serghei Chercheja
Galan Patricia Perez
Federico Medda
Steffen Josef Daum
Original Assignee
Centurion Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centurion Biopharma Corp filed Critical Centurion Biopharma Corp
Publication of MX2020005472A publication Critical patent/MX2020005472A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente materia proporciona profármacos de unión a albúmina, compuestos a base de maitansinoide y sus usos.
MX2020005472A 2017-11-30 2018-11-30 Sistemas de administración de fármacos a base de maitansinoide. MX2020005472A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762593184P 2017-11-30 2017-11-30
PCT/US2018/063380 WO2019108975A1 (en) 2017-11-30 2018-11-30 Maytansinoid-based drug delivery systems

Publications (1)

Publication Number Publication Date
MX2020005472A true MX2020005472A (es) 2020-11-11

Family

ID=64744962

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005472A MX2020005472A (es) 2017-11-30 2018-11-30 Sistemas de administración de fármacos a base de maitansinoide.

Country Status (11)

Country Link
US (2) US11572373B2 (es)
EP (1) EP3717018A1 (es)
JP (2) JP7442821B2 (es)
KR (1) KR20200117988A (es)
CN (1) CN111712263A (es)
AU (1) AU2018375788A1 (es)
BR (1) BR112020010989A2 (es)
CA (1) CA3083985A1 (es)
IL (2) IL274920B2 (es)
MX (1) MX2020005472A (es)
WO (1) WO2019108975A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3954394A1 (en) 2015-06-19 2022-02-16 Centurion BioPharma Corporation Delivery systems for controlled drug release
EP4344747A3 (en) 2017-11-30 2024-07-03 LadRx Corporation Albumin-binding prodrugs of auristatin e derivatives
CN110227164B (zh) * 2018-03-06 2021-11-23 江苏吉贝尔药业股份有限公司 含酮羰基的疏水性抗肿瘤药物及其缀合物、含有缀合物的纳米制剂及其制备方法及应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4125704A (en) 1977-09-14 1978-11-14 Sri International Phenyl-substituted rubidazone analogs
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0318554B2 (en) 1987-05-21 2005-01-12 Micromet AG Targeted multifunctional proteins
US4966999A (en) 1988-06-07 1990-10-30 Cytogen Corporation Radiohalogenated compounds for site specific labeling
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
CA2119930C (en) 1991-09-23 2002-10-01 Hendricus R. J. M. Hoogenboom Production of chimeric antibodies - a combinatorial approach
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
AU2004296191B2 (en) 2003-12-04 2010-10-28 Albany Molecular Research, Inc. Vinca derivatives
EP2152312B1 (en) 2007-05-16 2014-12-31 KTB Tumorforschungsgesellschaft mbH Low-viscous anthracycline formulation
EP2289558A1 (en) 2009-08-25 2011-03-02 KTB Tumorforschungsgesellschaft mbH Bisphosphonate-prodrugs
US9156854B2 (en) * 2011-04-18 2015-10-13 Immunogen, Inc. Maytansinoid derivatives with sulfoxide linker
PE20141790A1 (es) 2011-11-17 2014-11-27 Pfizer Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos
EP2630971B8 (en) 2012-02-21 2017-12-13 Vergell Medical S.A. Combinations of albumin-based drug delivery systems
US10131682B2 (en) 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
CN103333179B (zh) 2012-12-21 2017-06-16 百奥泰生物科技(广州)有限公司 类美登素衍生物及其制备方法和用途
US20140221429A1 (en) 2013-02-04 2014-08-07 Saud Ibrahim Al-Resayes Heterocyclic schiff's bases as novel and new antiglycation agents
EP3566750A3 (en) * 2013-02-28 2020-04-08 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
US20160375147A1 (en) 2015-03-27 2016-12-29 Regeneron Pharmaceuticals, Inc. Maytansinoid derivatives, conjugates thereof, and methods of use
ES2882631T3 (es) 2015-06-15 2021-12-02 Abbott Diabetes Care Inc Enzimas sensibles a lactato estabilizadas, electrodos y sensores y procedimientos para fabricar y utilizar las mismas
EP3954394A1 (en) * 2015-06-19 2022-02-16 Centurion BioPharma Corporation Delivery systems for controlled drug release
EP4344747A3 (en) 2017-11-30 2024-07-03 LadRx Corporation Albumin-binding prodrugs of auristatin e derivatives

Also Published As

Publication number Publication date
CA3083985A1 (en) 2019-06-06
JP2021505551A (ja) 2021-02-18
RU2020121456A (ru) 2021-12-30
EP3717018A1 (en) 2020-10-07
IL274920B2 (en) 2024-01-01
AU2018375788A1 (en) 2020-07-09
RU2020121456A3 (es) 2022-04-13
IL274920B1 (en) 2023-09-01
WO2019108975A1 (en) 2019-06-06
IL305268A (en) 2023-10-01
JP2023164604A (ja) 2023-11-10
IL274920A (en) 2020-07-30
CN111712263A (zh) 2020-09-25
KR20200117988A (ko) 2020-10-14
US20200385403A1 (en) 2020-12-10
BR112020010989A2 (pt) 2020-11-17
JP7442821B2 (ja) 2024-03-05
US11572373B2 (en) 2023-02-07
US20230391794A1 (en) 2023-12-07

Similar Documents

Publication Publication Date Title
GB201802837D0 (en) Awrosol delivery system
EP3287400A4 (en) Delivery system
MX2022015755A (es) Profarmacos de hormona paratiroidea (pth).
EP3287399A4 (en) Delivery system
MY195009A (en) Cellular Targeted Active Ingredient Delivery System
IL276784A (en) Drug delivery systems
EP3435978A4 (en) RELEASE SYSTEM
IL268773A (en) Systems for topical transfer of active compounds
EP3313499A4 (en) DEVICES, SYSTEMS AND METHODS FOR INCREASING THE INTRALUMINAL DRUG DELIVERY AND RECEIVING
MX2020003760A (es) Formulaciones de niraparib.
EP3310800A4 (en) ADMINISTRATION SYSTEMS FOR CONTROLLED RELEASE OF MEDICAMENTS
PH12016501841A1 (en) Immunosuppressant formulation
EP3826515A4 (en) DIRECTED DELIVERY SYSTEM
MX2020004424A (es) Formulacion aerosolizable.
MX2020004014A (es) Sistema optimizado de protocolo de seguridad de cabecera.
EP3740212A4 (en) CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY
GB202012051D0 (en) Delivery systems
EP3684156A4 (en) COMPONENT FEEDING SYSTEM
MX2020005472A (es) Sistemas de administración de fármacos a base de maitansinoide.
MX2019015167A (es) Farmacos antivirales.
EP3463589A4 (en) PERFUME DISTRIBUTION SYSTEM
PH12016501733A1 (en) Pharmaceutical composition for preventing or treating skin rash
EP3609474A4 (en) COLD WATER DISPERSABLE CHEMICAL DISPENSING SYSTEM
EP3609508A4 (en) DRUG DELIVERY SYSTEM FOR THE DELIVERY OF ANTIVIRAL AGENTS
PH12017502148A1 (en) Pharmaceutical compositions and use thereof